Principia Presents Phase 1 Data of PRN1371 in Patients with Metastatic Bladder Cancer

NEXT STORY
BeyondSpring Abstract Demonstrating Bone Pain Benefit with Lead Asset, Plinabulin, versus Neulasta for Neutropenia Prevention Presented at ISPOR 2019
PREV STORY
Results of Dyspnea Study Using Dynamic Digital Radiography to be Presented at ATS 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Victoza® significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes in the LEADER trial

New Orleans, US, 13 June 2016 - Novo Nordisk today announced that Victoza® (liraglutide) significantly ...

author_avatar
NASDAQ Market News

Stemline Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage ...

author_avatar
NASDAQ Market News

Innate Pharma reports first half 2018 financial results and business update

InNate Pharma REports first Half 2018 Financial Results and Business Update Preliminary anti-tumor activity ...

author_avatar
NASDAQ Market News